NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free ALT Stock Alerts $7.72 +0.56 (+7.82%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$7.17▼$8.0850-Day Range$6.40▼$12.0952-Week Range$2.09▼$14.84Volume4.34 million shsAverage Volume5.11 million shsMarket Capitalization$547.27 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Altimmune alerts: Email Address Altimmune MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside94.3% Upside$15.00 Price TargetShort InterestBearish28.73% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 24 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.52) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.90 out of 5 starsMedical Sector803rd out of 915 stocksPharmaceutical Preparations Industry384th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAltimmune has only been the subject of 3 research reports in the past 90 days.Read more about Altimmune's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted28.73% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Altimmune has recently increased by 14.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALT. Previous Next 1.7 News and Social Media Coverage News SentimentAltimmune has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Altimmune this week, compared to 4 articles on an average week.Search InterestOnly 55 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Altimmune are expected to decrease in the coming year, from ($1.52) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceProof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…Go here now for full story. About Altimmune Stock (NASDAQ:ALT)Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Read More ALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALT Stock News HeadlinesApril 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.April 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (ALT)The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolioMay 10, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…May 9, 2024 | stockhouse.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 9, 2024 | prnewswire.comINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law FirmMay 9, 2024 | msn.comALT Stock Earnings: Altimmune Beats EPS for Q1 2024May 9, 2024 | finanznachrichten.deAltimmune, Inc: Altimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateMay 9, 2024 | globenewswire.comAltimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateMay 10, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…May 8, 2024 | prnewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 8, 2024 | markets.businessinsider.comAltimmune earnings: here's what Wall Street expectsMay 8, 2024 | tmcnet.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsMay 8, 2024 | stockhouse.comALTIMMUNE, INC. (NASDAQ:ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming DeadlineMay 8, 2024 | americanbankingnews.comAltimmune (ALT) Scheduled to Post Earnings on ThursdayMay 8, 2024 | msn.comClass Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors – Contact Levi & Korsinsky LLPMay 7, 2024 | prnewswire.comALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 7, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsMay 7, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of InvestorsMay 7, 2024 | businesswire.comROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALTMay 7, 2024 | cnbc.comAmgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominanceMay 7, 2024 | benzinga.comJim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment'May 7, 2024 | globenewswire.comAltimmune to Participate at Two Upcoming Investor ConferencesMay 6, 2024 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Altimmune, Inc. and Certain Officers - ALTMay 6, 2024 | stockhouse.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 3, 2024 | msn.comAmgen stock rallies 13% on GLP-1 weight-loss drug updateMay 2, 2024 | globenewswire.comAltimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024May 1, 2024 | globenewswire.comAltimmune to Participate at Two Upcoming ConferencesSee More Headlines Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALT CUSIPN/A CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees59Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+94.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,450,000.00 Net Margins-20,780.75% Pretax Margin-20,762.21% Return on Equity-44.77% Return on Assets-40.72% Debt Debt-to-Equity RatioN/A Current Ratio17.26 Quick Ratio17.26 Sales & Book Value Annual Sales$430,000.00 Price / Sales1,272.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book2.81Miscellaneous Outstanding Shares70,890,000Free Float67,988,000Market Cap$547.27 million OptionableOptionable Beta0.22 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Vipin K. Garg Ph.D. (Age 66)President, CEO & Director Comp: $986.14kDr. Matthew Scott Harris AGAF (Age 71)FCAP, M.D., MS, Chief Medical Officer Comp: $681.81kMr. Raymond M. Jordt M.B.A. (Age 51)Chief Business Officer Comp: $578.85kMr. Richard I. Eisenstadt M.B.A. (Age 66)Chief Financial Officer Comp: $619.69kMr. Bertrand Georges Ph.D.Chief Technology OfficerDr. M. Scot Roberts Ph.D. (Age 65)Chief Scientific Officer Comp: $599.25kMr. Tony Blandin B.S.Vice President of Quality & Compliance ManagementMr. Andrew Shutterly M.S.Corporate ControllerMore ExecutivesKey CompetitorsKalVista PharmaceuticalsNASDAQ:KALVVerve TherapeuticsNASDAQ:VERVTravere TherapeuticsNASDAQ:TVTXLarimar TherapeuticsNASDAQ:LRMROculisNASDAQ:OCSView All CompetitorsInsiders & InstitutionsEntropy Technologies LPBought 34,527 shares on 5/8/2024Ownership: 0.049%Swiss National BankBought 106,000 shares on 5/7/2024Ownership: 0.150%Sei Investments Co.Bought 47,079 shares on 5/7/2024Ownership: 0.066%SG Americas Securities LLCBought 16,078 shares on 5/7/2024Ownership: 0.056%Bernardo Wealth Planning LLCBought 11,913 shares on 5/7/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions ALT Stock Analysis - Frequently Asked Questions Should I buy or sell Altimmune stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALT shares. View ALT analyst ratings or view top-rated stocks. What is Altimmune's stock price target for 2024? 4 brokerages have issued 12 month target prices for Altimmune's shares. Their ALT share price targets range from $12.00 to $20.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 94.3% from the stock's current price. View analysts price targets for ALT or view top-rated stocks among Wall Street analysts. How have ALT shares performed in 2024? Altimmune's stock was trading at $11.25 at the beginning of 2024. Since then, ALT shares have decreased by 31.4% and is now trading at $7.72. View the best growth stocks for 2024 here. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) issued its earnings results on Wednesday, March, 27th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.02. The company had revenue of $0.04 million for the quarter. Altimmune had a negative trailing twelve-month return on equity of 44.77% and a negative net margin of 20,780.75%. What ETF holds Altimmune's stock? Amplify Treatments, Testing and Advancements ETF holds 12,706 shares of ALT stock, representing 0.93% of its portfolio. When did Altimmune's stock split? Shares of Altimmune reverse split on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Pfizer (PFE), Verizon Communications (VZ), Amarin (AMRN), Advanced Micro Devices (AMD), Albireo Pharma (ALBO), Alliance Data Systems (ADS), AcelRx Pharmaceuticals (ACRX), Albertsons Companies (ACI) and Achieve Life Sciences (ACHV). Who are Altimmune's major shareholders? Altimmune's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Gerber LLC (0.40%), IMC Chicago LLC (0.00%), Simplex Trading LLC (0.00%), Swiss National Bank (0.15%), Commonwealth Equity Services LLC (0.11%) and GSA Capital Partners LLP (0.07%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris, Vipin K Garg and Wayne Pisano. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALT) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
